Next Phase Newsletter

A venture capital firm founded and headquartered in Taiwan is overall focused on investing in biotech and tech-related companies such as AI, biotech, medical device, pharma, fintech, semiconductors, smart manufacturing, etc. The firm is stage agnostic, however, within life science and healthcare, the firm is also focusing on early-stage companies from Pre-Series A to Series B. Typical check sizes range from $1M-10M, although usually it will be $3M-5M to start. The firm participates in co-investing, but 60-70% of the time, the firm will lead. The firm is looking at companies in the U.S., Japan, Taiwan, and Central Eastern Europe, with the goal of creating a cross-border ecosystem that helps healthcare and biotech companies thrive. The firm is also willing to help later-stage companies with commercialization and connect with Taiwanese partners and key players in the U.S. 
 
The firm invests in fundamental science driven companies with a technology focus. The main sectors the company focuses on are chronic disease management/treatment, AI and/or digital health, and service-based companies. Main indication areas include oncology, metabolic diseases, and autoimmune diseases, however indication areas are not limited to those listed. The firm is also open to orphan diseases, however, it has to be a platform that addresses orphan diseases to validate the technology. The firm looks at in-development and clinical stages as well as pre-approval, but they may not be interested in very early stages. For drugs, the firm requires proof of biology with an established animal model data. 
 
The firm may invest in young teams to grow with them, however most of the time, the firm prefers companies to have an experienced team in place. The firm also requires taking a board seat, if not, at least an observer seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm specialized in life sciences and medical technology, managing both RMB and USD funds with a total size of $1.5B, is operated by a professional team with diversified and profound industry backgrounds, having made over 90 investments with high growth potential since 2014. Typical Allocations Size of the firm’s RMB fund is 30MM-150MM in RMB, and up to 200MM in RMB; for the USD fund, the firm invests $5-10MM+ on average, and up to $20MM. 
 
The firm is open to investing in general Bio-medical industries globally, including diagnostics, medical devices, therapeutics and AI in the healthcare service platform. Especially, the firm is interested in medical imaging, minimally invasive diagnosis specially IVD and treatment, diagnostic reagents and mobile health. The firm prefers diagnostics companies that are at the growth stage but are looking for biotech companies in the seed stage. The firm is not interested in small molecules nor antibodies for now. 
 
The firm prefers companies that are tech-driven, commercially viable and are able to solve the real problem. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An investment firm headquartered in the US focuses on investing in public and private healthcare companies. In terms of early-stage companies, the firm is stage-agnostic with check sizes ranging from $10M-40M USD at the Series A round. The firm has a heavy bias for U.S.-based companies but may look at the EU. 
 
The firm is stage-, modality-, and indication-agnostic. For therapeutics, interests include genetically driven assets and novel biology/target/MoA. The firm typically does not invest in companies, for example, vaccine or immune-oncology companies unless there is clinical or human data. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

An investment bank based in the US actively seeks new investment opportunities. The firm does not act as a traditional investment bank, as they participate in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public market. The firm generally does not look at digital health. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes their sister company to further analyze company technologies and IPs. The firm can fund from $5M-12M USD from Seed to Series A rounds with preference in US-based companies, though open to global companies. 
 
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS. 
 
The firm works closely with companies and founder and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture builder and fund is looking to invest in US-based neurotechnology device companies advancing transformative diagnostics and therapies. The firm offers 3 different opportunities to support companies: (1) grants to academic researchers whose research aligns with the firm’s interests, (2) venture creation where the firm helps founders create, augment, and support companies, and (3) traditional equity investing. The firm engages in Pre-Seed to Series A rounds with typical check sizes ranging from $250k-2M USD. 
 
The firm primarily invests in medical devices that address stress and anxiety, sleep, and pain. The firm is open to working with companies from in-development stages. The firm is also open to take a leap on long-shot technologies that have potential to make significant changes in the neurotechnology space. 
 
The firm does not have specific management team requirements and typically does not lead. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   
 

Founded in 2010, with headquarters in Shanghai (China) and additional operations in USA, a global biopharmaceutical company has a vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology and immunology. The firm has launched 5 products in China, 1 in overseas markets (including EU) during past 4 years. 
 
The firm is seeking to in-license innovative assets and platforms in oncology that have synergies with the company’s current portfolio, in addition to seeking development and commercial partners for our oncology programs. 

The firm has no specific requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.   

A venture capital firm headquartered in Western Europe invests in healthcare companies with typical check size ranging from €1-20M EUR, participating starting from the 2nd or 3rd rounds of financing until Series B. The firm focuses on companies in the U.S. or Europe. 
 
The firm invests in diagnostics, digital health, and medical devices. The firm does not invest in drugs, biotech, or therapeutics. The firm invests in companies in the in-development or clinical stages. The firm is indication-agnostic. 
 
The firm does not have specific management team requirements. The firm typically takes a board or observer seat on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.